Phase 4 Heart Disease Trial, Recruiting (NCT05267886)

Phase 4 Heart Disease Trial, Recruiting NCT05267886 Sponsor: Ottawa Heart Institute Research Corporation Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05267886 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 or older who have been admitted to an intensive care unit
People who have been diagnosed with cardiogenic shock at a moderate or severe level (known as SCAI class C or D), meaning the heart is not pumping enough blood to meet the body's needs

Who may not be able to join:

People who are unable or unwilling to give consent to participate, and where no authorised substitute decision-maker is available to give consent on their behalf
People who are currently pregnant or breastfeeding
People who experienced a cardiac arrest outside of a hospital setting before being admitted
People who have received the heart medications milrinone or dobutamine in the 24 hours before the planned start of the trial
People who have a serious narrowing of certain heart valves, specifically the aortic valve or the mitral valve (confirm with trial site)
People who have a condition where the passage out of the heart's main pumping chamber becomes blocked during heartbeats (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Rebecca Mathew, MD, Ottawa Heart Institute Research Corporation

Phone: 613-696-7406

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05267886

Sponsor: Ottawa Heart Institute Research Corporation

Phase: Phase 4

Status: Recruiting

Condition: Heart Disease

Trial contact: 613-696-7406

More information: https://clinicaltrials.gov/study/NCT05267886

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 or older who have been admitted to an intensive care unit
People who have been diagnosed with cardiogenic shock at a moderate or severe level (known as SCAI class C or D), meaning the heart is not pumping enough blood to meet the body's needs

Who may not be able to join:

People who are unable or unwilling to give consent to participate, and where no authorised substitute decision-maker is available to give consent on their behalf
People who are currently pregnant or breastfeeding
People who experienced a cardiac arrest outside of a hospital setting before being admitted
People who have received the heart medications milrinone or dobutamine in the 24 hours before the planned start of the trial
People who have a serious narrowing of certain heart valves, specifically the aortic valve or the mitral valve (confirm with trial site)
People who have a condition where the passage out of the heart's main pumping chamber becomes blocked during heartbeats (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Ottawa Heart Institute Research Corporation

Registry

ClinicalTrials.gov

Start date

5 March 2022

Est. completion

1 December 2026

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

Primary composite outcome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov